DOCSLIB.ORG

(TRPM) Channel Gene Polymorphisms in Obesity-Related Metabolic Syndrome

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Eur opean Rev iew for Med ical and Pharmacol ogical Sci ences 2015; 19: 1388-1397 Role of the transient receptor potential (TRP) channel gene expressions and TRP melastatin (TRPM) channel gene polymorphisms in obesity-related metabolic syndrome S. TABUR 1, S. OZTUZCU 2, I.V. DUZEN 3, A. ERAYDIN 1, S. EROGLU 2, M. OZKAYA 1, A.T. DEMIRYÜREK 4 1Division of Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey 2Department of Medical Biology, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey 3Department of Cardiology, 25 Aralık State Hospital, Gaziantep, Turkey 4Department of Medical Pharmacology, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey Abstract. – OBJECTIVE: Metabolic syndrome This study also revealed that there is a signifi - (MetS) is correlated with increased cardiovascu - cant relationship between TRP channels gene lar risk and characterized by several factors, in - expressions and MetS. cluding visceral obesity, hypertension, dyslipi - demia, and insulin resistance. The etiology of Key Words: MetS is complex, and can be influenced by ge - Expression, Gene variants, Metabolic syndrome, netic susceptibility. The aim of this study was to Obesity, Transient receptor potential. investigate a possible association of transient receptor potential (TRP) channels gene expres - sions and TRP melastatin (TRPM) gene polymor - Introduction phisms with MetS in a Turkish population. PATIENTS AND METHODS: A total of 142 pa - Metabolic syndrome (MetS) is characterized tients with obesity-related MetS and 166 healthy controls with similar age and sex were enrolled by a combination of visceral obesity, hyperten - to this study. For polymorphism studies, genom - sion, insulin resistance, dyslipidemia, and im - ic DNA from the participants was analyzed by a paired glucose tolerance. Experimental, epidemi - BioMark 96.96 dynamic array system (Fluidigm, ological, and clinical studies have demonstrated South San Francisco, CA, USA). For gene ex - that patients with MetS have significantly elevat - pression studies, mRNA from blood samples ed cardiovascular morbidity and mortality 1. The was extracted, and real time polymerase chain 2 reaction on the BioMark HD system was per - prevalence of MetS is about 30% worldwide . formed. The prevalence of obesity and the MetS is rapid - RESULTS: There was an increase in A allele ly increasing, leading to increased morbidity and (64.6% in patients vs. 49.5% in controls) and de - mortality. A survey in Turkey reported a preva - crease in G allele frequencies (35.4% in patients lence of 33.9% for the MetS, with a higher vs. 50.5% in control, p = 0.0019) of the TRPM5 prevalence in women (39.6%) than in men gene rs4929982 (Arg578Gln) polymorphism. We (28%) 3. The prevalence of MetS was also found also observed that the distribution of genotype and allele frequencies of the TRPM8 gene to be 37.5% in Turkish patients with non-diabetic 4 rs12472151 in MetS patients were significantly first acute ST elevation myocardial infarction . different from controls ( p < 0.0001). Although The exact cause of MetS is not known. Several there were marked decreases in TRPC1, TRPC3, studies have found that people with higher calci - TRPM2, TRPM5, TRPV4, TRPV5, TRPV6, MCOLN2 um intakes have a lower prevalence of MetS and (TRPML2), and MCOLN3 (TRPML3) gene expres - its components 5-7 . Calcium is known to play a sions, an augmentation was noted in TRPC6 gene expression. key role in blood pressure control and adipocyte CONCLUSIONS : Genetic polymorphisms in metabolism, and thus its effects on MetS could TRPM5 and TRPM8 genes may modify individual be partially mediated by its effects on body fat, susceptibility to MetS in the Turkish population. blood pressure, and insulin sensitivity 8. 1388 Corresponding Author: Suzan Tabur, MD; e-mail: [email protected] TRP channels in metabolic syndrome Transient receptor potential (TRP) channels controls evaluated at Division of Endocrinology, are the recently discovered major ion channel su - Department of Internal Medicine, Faculty of perfamily. There are 28 mammalian TRP chan - Medicine, Gaziantep University, Gaziantep, nels, which are subdivided into six subfamilies Turkey were recruited into this study. The study based on protein sequence homology: TRPC for was approved by the local Ethics Committee, and “canonical” (TRPC1–7), TRPV for “vanilloid” written informed consent prior to participation in (TRPV1–6), TRPM for “melastatin” (TRPM1– the study was obtained from patients and healthy 8), TRPP for “polycystin” (TRPP2, TRPP3, volunteers according to the Declaration of TRPP5), TRPML for “mucolipin” (TRPML1–3), Helsinki. and TRPA for “ankyrin” (TRPA1) 9,10 . TRP chan - MetS was defined by using modified criteria nels are non-selective channels permeable to proposed by the Third Report of the National monovalent and divalent cations. Thus, changes Cholesterol Education Program Adult Treatment in the function or expression of TRP channels Panel 22,23 . A MetS diagnosis was made when a could alter intracellular Ca 2+ levels directly, indi - subject fulfilled three of the following five crite - rectly or through membrane potential and the ria: waist circumference 102 cm in men and 2+ 11 ≥ ≥ regulation of L-type Ca channel activity . 88 cm in women, triglyceride (TG) ≥ 150 mg/dl TRP channels are broadly distributed in sever - or treatment of dyslipidemia, high density al cell types, including adipocytes, vascular lipoprotein (HDL ) cholesterol < 40 mg/dl in men smooth muscle cells and endothelial cells, which and < 50 mg/dl in women or treatment of dyslipi - explains their wide spread function. Thus demia, systolic and diastolic blood pressure ≥ changes in expression or disturbance of TRP 130 and 85 mm Hg or antihypertensive treat - channel function likely result in the development ment, and fasting blood glucose ≥ 100 mg/dl or of MetS. Oxidative stress is known to play a ma - treatment of type 2 diabetes. Patients who had a jor role in the pathogenesis of MetS 12-14 . TRPM history of percutaneous coronary intervention channels are also activated by oxidative stress 10 . within 6 months or coronary artery bypass Our hypothesis is that the TRPM polymorphisms surgery within 1 year were excluded. Other ex - or gene expressions are associated with MetS. clusion criteria included patients who had heart The progression of MetS is influenced by genetic failure, cardiomyopathy, or valvular heart dis - susceptibility and environmental factors, including eases. All patients were in the follow up of the diet, and the interactions between them 15-17 . Heri - Endocrinology Clinic. tability estimates of the MetS range from 13% to All sex and age-matched controls were healthy 27% 18,19 . Recently, published genome-wide associa - and had no symptoms of MetS. The selection cri - tion studies have described candidate genes, includ - teria of the controls were that all control subjects ing fat mass and obesity associated ( FTO ) and were from the same geographical area with a melanocortin 4 receptor ( MC4R ) genes, that con - similar socioeconomic and ethnic background tribute to MetS and its phenotypes around the and were admitted to outpatient clinic. The so - world 20,21 . Changes of TRP channel gene expres - cioeconomic background was identified by the sions or polymorphisms may account for the ob - information obtained from the patient and the served increased cardiovascular risk in MetS pa - controls through a health questionnaire. All the tients. A finding of gene-calcium interactions could patients and controls were in the middle income improve our understanding of the mechanisms of status. Exclusion criteria for selecting control metabolic alterations and could eventually lead to subjects were presence of coronary artery dis - effective, personalized prevention of MetS. Thus, in ease, peripheral occlusive arterial disease, coagu - this study we aimed to investigate whether TRP lopathy, vasculitis, autoimmune disease, severe channel gene expressions and TRPM gene poly - kidney and hepatic diseases, cancer, and preg - morphisms are associated with susceptibility to nancy. obesity-related MetS in a Turkish population. Biochemical Analysis Venous blood samples were drawn from each Patients and Methods subject after ≥ 8 h or overnight fasting. The sam - ples were stored at –80°C until biochemical as - Study Populations say by blinded investigators. All routine chem - A total of 308 unrelated Turkish subjects, 14 2 istry was conducted by the standard laboratory with obesity-related MetS and 166 non-MetS techniques in the Clinical Biochemistry Labora - 1389 S. Tabur, S. Oztuzcu, I.V. Duzen, A. Eraydin, S. Eroglu, M. Ozkaya, A.T. Demiryürek tory. Triglycerides were determined enzymatical - PKD2 (TRPP2) ] for expression study. Data were ly. High-density lipoprotein cholesterol was mea - analyzed using the 2 -∆Ct method, according to the sured by the phosphotungstate method. Glucose formula: ∆Ct = C tTR – C tACTB , where C t = thresh - was enzymatically determined by the hexokinase old cycle. method. Statistical Analysis Blood Samples and DNA Isolation Results are expressed as the means ± S.D. or Peripheral venous blood samples (5 ml) were percentage otherwise indicated. The Chi-square collected by venipuncture into sterile siliconized test for independence, Chi-square test with Yate’s Vacutainer tubes with 2 mg/ml disodium ethyl - correction or Fisher’s exact tests were used for enediaminetetraacetic acid. All
Recommended publications
  • The Structural Basis for an On–Off Switch Controlling Gβγ-Mediated Inhibition of TRPM3 Channels

    The Structural Basis for an On–Off Switch Controlling Gβγ-Mediated Inhibition of TRPM3 Channels

    The structural basis for an on–off switch controlling Gβγ-mediated inhibition of TRPM3 channels Marc Behrendta,b,1,2, Fabian Grussc,1,3, Raissa Enzerotha,b, Sandeep Demblaa,b, Siyuan Zhaod, Pierre-Antoine Crassousd, Florian Mohra, Mieke Nysc, Nikolaos Lourose, Rodrigo Gallardoe,4, Valentina Zorzinif,5, Doris Wagnera, Anastassios Economou (Αναστάσιoς Οικoνόμoυ)f, Frederic Rousseaue, Joost Schymkowitze, Stephan E. Philippg, Tibor Rohacsd, Chris Ulensc,6, and Johannes Oberwinklera,b,6 aInstitut für Physiologie und Pathophysiologie, Philipps-Universität Marburg, 35037 Marburg, Germany;bCenter for Mind, Brain and Behavior (CMBB), Philipps-Universität Marburg and Justus-Liebig-Universität Giessen, 35032 Marburg, Germany; cLaboratory of Structural Neurobiology, Department of Cellular and Molecular Medicine, KU Leuven, 3000 Leuven, Belgium; dDepartment of Pharmacology, Physiology and Neuroscience, Rutgers New Jersey Medical School, Newark, NJ 07103; eSwitch Laboratory, VIB Center for Brain and Disease Research, Department of Cellular and Molecular Medicine, KU Leuven, 3000 Leuven, Belgium; fLaboratory of Molecular Bacteriology, Department of Microbiology and Immunology, Rega Institute for Medical Research, KU Leuven, 3000 Leuven, Belgium; and gExperimentelle und Klinische Pharmakologie und Toxikologie, Universität des Saarlandes, 66421 Homburg, Germany Edited by László Csanády, Semmelweis University, Budapest, Hungary, and accepted by Editorial Board Member David E. Clapham August 27, 2020 (received for review February 13, 2020) TRPM3 channels play important roles in the detection of noxious also subject to inhibition by activated μORsorotherGPCRs(6, heat and in inflammatory thermal hyperalgesia. The activity of 24–28), a process that has been shown to take place in peripheral these ion channels in somatosensory neurons is tightly regulated by endings of nociceptive neurons since locally applied μOR or μ βγ -opioid receptors through the signaling of G proteins, thereby GABA receptor agonists inhibit TRPM3-dependent pain (24–26).
  • The Intracellular Ca2+ Release Channel TRPML1 Regulates Lower Urinary Tract Smooth Muscle Contractility

    The Intracellular Ca2+ Release Channel TRPML1 Regulates Lower Urinary Tract Smooth Muscle Contractility

    The intracellular Ca2+ release channel TRPML1 regulates lower urinary tract smooth muscle contractility Caoimhin S. Griffina, Michael G. Alvaradoa, Evan Yamasakia, Bernard T. Drummb,c, Vivek Krishnana, Sher Alia, Eleanor M. Naglea, Kenton M. Sandersb, and Scott Earleya,1 aDepartment of Pharmacology, Center for Molecular and Cellular Signaling in the Cardiovascular System, Reno School of Medicine, University of Nevada, Reno, NV 89557-0318; bDepartment of Physiology and Cell Biology, Reno School of Medicine, University of Nevada, Reno, NV 89557-0318; and cDepartment of Life & Health Sciences, Dundalk Institute of Technology, Louth, Ireland A91 K584 Edited by Mark T. Nelson, University of Vermont, Burlington, VT, and approved October 13, 2020 (received for review August 12, 2020) TRPML1 (transient receptor potential mucolipin 1) is a Ca2+-perme- including dense granulomembranous storage bodies in neurons, able, nonselective cation channel that is predominantly localized to elevated plasma gastrin, vacuolization in the gastric mucosa, and the membranes of late endosomes and lysosomes (LELs). Intracellular retinal degeneration (14). Interestingly, however, an anatomical release of Ca2+ through TRPML1 is thought to be pivotal for mainte- examination of these mice reveals dramatically distended bladders nance of intravesicular acidic pH as well as the maturation, fusion, and (14), leading us to question how TRPML1, an intracellular Ca2+-re- trafficking of LELs. Interestingly, genetic ablation of TRPML1 in mice lease channel important in LEL function, affects bladder physiology. −/− (Mcoln1 ) induces a hyperdistended/hypertrophic bladder phenotype. The lower urinary tract (LUT) is composed of the urinary Here, we investigated this phenomenon further by exploring an un- bladder and urethra—structures that serve the simple, reciprocal conventional role for TRPML1 channels in the regulation of Ca2+-signal- functions of storing and voiding urine (15).
  • The Intracellular Ca2+ Release Channel TRPML1 Regulates Lower Urinary Tract Smooth Muscle Contractility

    The Intracellular Ca2+ Release Channel TRPML1 Regulates Lower Urinary Tract Smooth Muscle Contractility

    The intracellular Ca2+ release channel TRPML1 regulates lower urinary tract smooth muscle contractility Caoimhin S. Griffina, Michael G. Alvaradoa, Evan Yamasakia, Bernard T. Drummb,c, Vivek Krishnana, Sher Alia, Eleanor M. Naglea, Kenton M. Sandersb, and Scott Earleya,1 aDepartment of Pharmacology, Center for Molecular and Cellular Signaling in the Cardiovascular System, Reno School of Medicine, University of Nevada, Reno, NV 89557-0318; bDepartment of Physiology and Cell Biology, Reno School of Medicine, University of Nevada, Reno, NV 89557-0318; and cDepartment of Life & Health Sciences, Dundalk Institute of Technology, Louth, Ireland A91 K584 Edited by Mark T. Nelson, University of Vermont, Burlington, VT, and approved October 13, 2020 (received for review August 12, 2020) TRPML1 (transient receptor potential mucolipin 1) is a Ca2+-perme- including dense granulomembranous storage bodies in neurons, able, nonselective cation channel that is predominantly localized to elevated plasma gastrin, vacuolization in the gastric mucosa, and the membranes of late endosomes and lysosomes (LELs). Intracellular retinal degeneration (14). Interestingly, however, an anatomical release of Ca2+ through TRPML1 is thought to be pivotal for mainte- examination of these mice reveals dramatically distended bladders nance of intravesicular acidic pH as well as the maturation, fusion, and (14), leading us to question how TRPML1, an intracellular Ca2+- trafficking of LELs. Interestingly, genetic ablation of TRPML1 in mice release channel important in LEL function, affects bladder −/− (Mcoln1 ) induces a hyperdistended/hypertrophic bladder phenotype. physiology. Here, we investigated this phenomenon further by exploring an un- The lower urinary tract (LUT) is composed of the urinary conventional role for TRPML1 channels in the regulation of Ca2+-signal- bladder and urethra—structures that serve the simple, reciprocal ing activity and contractility in bladder and urethral smooth muscle cells functions of storing and voiding urine (15).
  • The TRPP2-Dependent Channel of Renal Primary Cilia Also Requires TRPM3

    The TRPP2-Dependent Channel of Renal Primary Cilia Also Requires TRPM3

    The TRPP2-dependent channel of renal primary cilia also requires TRPM3 Steven J. Kleene1, Brian J. Siroky2, Julio A. Landero-Figueroa3, Bradley P. Dixon4, Nolan W. Pachciarz2, Lu Lu2, and Nancy K. Kleene1 1Department of Pharmacology and Systems Physiology, University of Cincinnati, Cincinnati, Ohio; 2Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; 3Department of Chemistry, University of Cincinnati, Cincinnati, Ohio; 4Renal Section, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado IntroductIon Primary cilia of renal epithelial cells express several members of the transient receptor potential (TRP) class of cation-conducting channel, including TRPC1, TRPM3, TRPM4, TRPP2, and TRPV4. Some cases of autosomal dominant polycystic kidney disease (ADPKD) are caused by defects in TRPP2 (also called polycystin-2, PC2, or PKD2). A large-conductance, TRPP2- dependent channel in renal cilia has been well described, but it is not known whether this channel includes any other protein subunits. Methods To study this question, we investigated the pharmacology of the TRPP2-dependent channel through electrical recordings from the cilia of mIMCD-3 cells, a murine cell line of renal epithelial origin, results The pharmacology was found to match that of TRPM3 channels. The ciliary TRPP2-dependent channel is known to be activated by depolarization and/or increasing cytoplasmic Ca2+. This activation was greatly enhanced by external pregnenolone sulfate, an agonist of TRPM3 channels. Pregnenolone sulfate did not change the current-voltage relation of the channel. CIM0216, another TRPM3 agonist, modestly increased the activity of the ciliary channels. The channels were effectively blocked by isosakuranetin, a specific inhibitor of TRPM3 channels.
  • The Direct and Functional Interaction of Tubulin with Transient Receptor Potential Melastatin 2

    The Direct and Functional Interaction of Tubulin with Transient Receptor Potential Melastatin 2

    The Direct and Functional Interaction of Tubulin With Transient Receptor Potential Melastatin 2 by Colin Elliott Seepersad A thesis submitted in conformity with the requirements for the degree of Masters of Science Cell & Systems Biology University of Toronto © Copyright by Colin Elliott Seepersad 2011 The Direct and Functional Interaction of Tubulin With Transient Receptor Potential Melastatin 2 Colin Elliott Seepersad Masters of Science Cell & Systems Biology University of Toronto 2011 Abstract Transient Receptor Potential Melastatin 2 (TRPM2) is a widely expressed, non-selective cationic channel with implicated roles in cell death, chemokine production and oxidative stress. This study characterizes a novel interactor of TRPM2. Using fusion proteins comprised of the TRPM2 C-terminus we established that tubulin interacted directly with the predicted C-terminal coiled-coil domain of the channel. In vitro studies revealed increased interaction between tubulin and TRPM2 during LPS-induced macrophage activation and taxol-induced microtubule stabilization. We propose that the stabilization of microtubules in activated macrophages enhances the interaction of tubulin with TRPM2 resulting in the gating and/or localization of the channel resulting in a contribution to increased intracellular calcium and downstream production of chemokines. ii Acknowledgments I would like to thank my supervisor Dr. Michelle Aarts for providing me with the opportunity to pursuit a Master’s of Science Degree at the University of Toronto. Since my days as an undergraduate thesis student, Michelle has provided me with the knowledge, tools and environment to succeed. I am very grateful for the experience and will move forward a more rounded and mature student. Special thanks to my committee members, Dr.
  • TRPC1 Regulates the Activity of a Voltage-Dependent Nonselective Cation Current in Hippocampal CA1 Neurons

    TRPC1 Regulates the Activity of a Voltage-Dependent Nonselective Cation Current in Hippocampal CA1 Neurons

    cells Article TRPC1 Regulates the Activity of a Voltage-Dependent Nonselective Cation Current in Hippocampal CA1 Neurons 1, 1 1,2 1,3, Frauke Kepura y, Eva Braun , Alexander Dietrich and Tim D. Plant * 1 Pharmakologisches Institut, BPC-Marburg, Fachbereich Medizin, Philipps-Universität Marburg, Karl-von-Frisch-Straße 2, 35043 Marburg, Germany; [email protected] (F.K.); braune@staff.uni-marburg.de (E.B.); [email protected] (A.D.) 2 Walther-Straub-Institut für Pharmakologie und Toxikologie, Ludwig-Maximilians-Universität München, 80336 München, Germany 3 Center for Mind, Brain and Behavior, Philipps-Universität Marburg, 35032 Marburg, Germany * Correspondence: plant@staff.uni-marburg.de; Tel.: +49-6421-28-65038 Present address: Institut für Bodenkunde und Pflanzenernährung/Institut für angewandte Ökologie, y Hochschule Geisenheim University, Von-Lade-Str. 1, 65366 Geisenheim, Germany. Received: 27 November 2019; Accepted: 14 February 2020; Published: 18 February 2020 Abstract: The cation channel subunit TRPC1 is strongly expressed in central neurons including neurons in the CA1 region of the hippocampus where it forms complexes with TRPC4 and TRPC5. To investigate the functional role of TRPC1 in these neurons and in channel function, we compared current responses to group I metabotropic glutamate receptor (mGluR I) activation and looked +/+ / for major differences in dendritic morphology in neurons from TRPC1 and TRPC1− − mice. mGluR I stimulation resulted in the activation of a voltage-dependent nonselective cation current in both genotypes. Deletion of TRPC1 resulted in a modification of the shape of the current-voltage relationship, leading to an inward current increase. In current clamp recordings, the percentage of neurons that responded to depolarization in the presence of an mGluR I agonist with a plateau / potential was increased in TRPC1− − mice.
  • Note: the Letters 'F' and 'T' Following the Locators Refers to Figures and Tables

    Note: the Letters 'F' and 'T' Following the Locators Refers to Figures and Tables

    Index Note: The letters ‘f’ and ‘t’ following the locators refers to figures and tables cited in the text. A Acyl-lipid desaturas, 455 AA, see Arachidonic acid (AA) Adenophostin A, 71, 72t aa, see Amino acid (aa) Adenosine 5-diphosphoribose, 65, 789 AACOCF3, see Arachidonyl trifluoromethyl Adlea, 651 ketone (AACOCF3) ADP, 4t, 10, 155, 597, 598f, 599, 602, 669, α1A-adrenoceptor antagonist prazosin, 711t, 814–815, 890 553 ADPKD, see Autosomal dominant polycystic aa 723–928 fragment, 19 kidney disease (ADPKD) aa 839–873 fragment, 17, 19 ADPKD-causing mutations Aβ, see Amyloid β-peptide (Aβ) PKD1 ABC protein, see ATP-binding cassette protein L4224P, 17 (ABC transporter) R4227X, 17 Abeele, F. V., 715 TRPP2 Abbott Laboratories, 645 E837X, 17 ACA, see N-(p-amylcinnamoyl)anthranilic R742X, 17 acid (ACA) R807X, 17 Acetaldehyde, 68t, 69 R872X, 17 Acetic acid-induced nociceptive response, ADPR, see ADP-ribose (ADPR) 50 ADP-ribose (ADPR), 99, 112–113, 113f, Acetylcholine-secreting sympathetic neuron, 380–382, 464, 534–536, 535f, 179 537f, 538, 711t, 712–713, Acetylsalicylic acid, 49t, 55 717, 770, 784, 789, 816–820, Acrolein, 67t, 69, 867, 971–972 885 Acrosome reaction, 125, 130, 301, 325, β-Adrenergic agonists, 740 578, 881–882, 885, 888–889, α2 Adrenoreceptor, 49t, 55, 188 891–895 Adult polycystic kidney disease (ADPKD), Actinopterigy, 223 1023 Activation gate, 485–486 Aframomum daniellii (aframodial), 46t, 52 Leu681, amino acid residue, 485–486 Aframomum melegueta (Melegueta pepper), Tyr671, ion pathway, 486 45t, 51, 70 Acute myeloid leukaemia and myelodysplastic Agelenopsis aperta (American funnel web syndrome (AML/MDS), 949 spider), 48t, 54 Acylated phloroglucinol hyperforin, 71 Agonist-dependent vasorelaxation, 378 Acylation, 96 Ahern, G.
  • Investigational Drugs in Early Phase Clinical Trials Targeting Thermotransient Receptor Potential (Thermotrp) Channels

    Investigational Drugs in Early Phase Clinical Trials Targeting Thermotransient Receptor Potential (Thermotrp) Channels

    Expert Opinion on Investigational Drugs ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/ieid20 Investigational drugs in early phase clinical trials targeting thermotransient receptor potential (thermoTRP) channels Asia Fernández-Carvajal , Rosario González-Muñiz , Gregorio Fernández- Ballester & Antonio Ferrer-Montiel To cite this article: Asia Fernández-Carvajal , Rosario González-Muñiz , Gregorio Fernández- Ballester & Antonio Ferrer-Montiel (2020): Investigational drugs in early phase clinical trials targeting thermotransient receptor potential (thermoTRP) channels, Expert Opinion on Investigational Drugs, DOI: 10.1080/13543784.2020.1825680 To link to this article: https://doi.org/10.1080/13543784.2020.1825680 Published online: 29 Sep 2020. Submit your article to this journal Article views: 31 View related articles View Crossmark data Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=ieid20 EXPERT OPINION ON INVESTIGATIONAL DRUGS https://doi.org/10.1080/13543784.2020.1825680 REVIEW Investigational drugs in early phase clinical trials targeting thermotransient receptor potential (thermoTRP) channels Asia Fernández-Carvajala, Rosario González-Muñizb, Gregorio Fernández-Ballestera and Antonio Ferrer-Montiela aInstituto De Investigación, Desarrollo E Innovación En Biotecnología Sanitaria De Elche (Idibe), Universitas Miguel Hernández, Alicante, Spain; bInstituto De Química Médica, CSIC, Madrid, Spain ABSTRACT ARTICLE HISTORY Introduction: Thermo transient receptor potential (thermoTRP) channels are some of the most inten­ Received 15 June 2020 sely pursued therapeutic targets of the past decade. They are considered promising targets of numer­ Accepted 15 September ous diseases including chronic pain and cancer. Modulators of these proteins, in particular TRPV1-4, 2020 TRPM8 and TRPA1, have reached clinical development, but none has been approved for clinical practice KEYWORDS yet.
  • TRP CHANNELS AS THERAPEUTIC TARGETS TRP CHANNELS AS THERAPEUTIC TARGETS from Basic Science to Clinical Use

    TRP CHANNELS AS THERAPEUTIC TARGETS TRP CHANNELS AS THERAPEUTIC TARGETS from Basic Science to Clinical Use

    TRP CHANNELS AS THERAPEUTIC TARGETS TRP CHANNELS AS THERAPEUTIC TARGETS From Basic Science to Clinical Use Edited by ARPAD SZALLASI MD, PHD Department of Pathology, Monmouth Medical Center, Long Branch, NJ, USA AMSTERDAM • BOSTON • HEIDELBERG • LONDON NEW YORK • OXFORD • PARIS • SAN DIEGO SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO Academic Press is an imprint of Elsevier Academic Press is an imprint of Elsevier 125 London Wall, London, EC2Y 5AS, UK 525 B Street, Suite 1800, San Diego, CA 92101-4495, USA 225 Wyman Street, Waltham, MA 02451, USA The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK First published 2015 Copyright © 2015 Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher’s permissions policies and our arrangement with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein). Notices Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary. Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein.
  • Snapshot: Mammalian TRP Channels David E

    Snapshot: Mammalian TRP Channels David E

    SnapShot: Mammalian TRP Channels David E. Clapham HHMI, Children’s Hospital, Department of Neurobiology, Harvard Medical School, Boston, MA 02115, USA TRP Activators Inhibitors Putative Interacting Proteins Proposed Functions Activation potentiated by PLC pathways Gd, La TRPC4, TRPC5, calmodulin, TRPC3, Homodimer is a purported stretch-sensitive ion channel; form C1 TRPP1, IP3Rs, caveolin-1, PMCA heteromeric ion channels with TRPC4 or TRPC5 in neurons -/- Pheromone receptor mechanism? Calmodulin, IP3R3, Enkurin, TRPC6 TRPC2 mice respond abnormally to urine-based olfactory C2 cues; pheromone sensing 2+ Diacylglycerol, [Ca ]I, activation potentiated BTP2, flufenamate, Gd, La TRPC1, calmodulin, PLCβ, PLCγ, IP3R, Potential role in vasoregulation and airway regulation C3 by PLC pathways RyR, SERCA, caveolin-1, αSNAP, NCX1 La (100 µM), calmidazolium, activation [Ca2+] , 2-APB, niflumic acid, TRPC1, TRPC5, calmodulin, PLCβ, TRPC4-/- mice have abnormalities in endothelial-based vessel C4 i potentiated by PLC pathways DIDS, La (mM) NHERF1, IP3R permeability La (100 µM), activation potentiated by PLC 2-APB, flufenamate, La (mM) TRPC1, TRPC4, calmodulin, PLCβ, No phenotype yet reported in TRPC5-/- mice; potentially C5 pathways, nitric oxide NHERF1/2, ZO-1, IP3R regulates growth cones and neurite extension 2+ Diacylglycerol, [Ca ]I, 20-HETE, activation 2-APB, amiloride, Cd, La, Gd Calmodulin, TRPC3, TRPC7, FKBP12 Missense mutation in human focal segmental glomerulo- C6 potentiated by PLC pathways sclerosis (FSGS); abnormal vasoregulation in TRPC6-/-
  • Involvement of TRPC4 and 5 Channels in Persistent Firing in Hippocampal CA1 Pyramidal Cells

    Involvement of TRPC4 and 5 Channels in Persistent Firing in Hippocampal CA1 Pyramidal Cells

    cells Article Involvement of TRPC4 and 5 Channels in Persistent Firing in Hippocampal CA1 Pyramidal Cells Alberto Arboit 1,2,3, Antonio Reboreda 1,4 and Motoharu Yoshida 1,3,4,5,* 1 German Center for Neurodegenerative Diseases (DZNE), 39120 Magdeburg, Germany; [email protected] (A.A.); [email protected] (A.R.) 2 Otto-von-Guericke University, 39120 Magdeburg, Germany 3 Faculty of Psychology, Ruhr University Bochum (RUB), Universitätsstraße 150, 44801 Bochum, Germany 4 Leibniz Institute for Neurobiology (LIN), 39118 Magdeburg, Germany 5 Center for Behavioral Brain Sciences (CBBS), 39106 Magdeburg, Germany * Correspondence: [email protected] Received: 1 December 2019; Accepted: 1 February 2020; Published: 5 February 2020 Abstract: Persistent neural activity has been observed in vivo during working memory tasks, and supports short-term (up to tens of seconds) retention of information. While synaptic and intrinsic cellular mechanisms of persistent firing have been proposed, underlying cellular mechanisms are not yet fully understood. In vitro experiments have shown that individual neurons in the hippocampus and other working memory related areas support persistent firing through intrinsic cellular mechanisms that involve the transient receptor potential canonical (TRPC) channels. Recent behavioral studies demonstrating the involvement of TRPC channels on working memory make the hypothesis that TRPC driven persistent firing supports working memory a very attractive one. However, this view has been challenged by recent findings that persistent firing in vitro is unchanged in TRPC knock out (KO) mice. To assess the involvement of TRPC channels further, we tested novel and highly specific TRPC channel blockers in cholinergically induced persistent firing in mice CA1 pyramidal cells for the first time.
  • Heteromeric TRP Channels in Lung Inflammation

    Heteromeric TRP Channels in Lung Inflammation

    cells Review Heteromeric TRP Channels in Lung Inflammation Meryam Zergane 1, Wolfgang M. Kuebler 1,2,3,4,5,* and Laura Michalick 1,2 1 Institute of Physiology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany; [email protected] (M.Z.); [email protected] (L.M.) 2 German Centre for Cardiovascular Research (DZHK), 10785 Berlin, Germany 3 German Center for Lung Research (DZL), 35392 Gießen, Germany 4 The Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Toronto, ON M5B 1W8, Canada 5 Department of Surgery and Physiology, University of Toronto, Toronto, ON M5S 1A8, Canada * Correspondence: [email protected] Abstract: Activation of Transient Receptor Potential (TRP) channels can disrupt endothelial bar- rier function, as their mediated Ca2+ influx activates the CaM (calmodulin)/MLCK (myosin light chain kinase)-signaling pathway, and thereby rearranges the cytoskeleton, increases endothelial permeability and thus can facilitate activation of inflammatory cells and formation of pulmonary edema. Interestingly, TRP channel subunits can build heterotetramers, whereas heteromeric TRPC1/4, TRPC3/6 and TRPV1/4 are expressed in the lung endothelium and could be targeted as a protec- tive strategy to reduce endothelial permeability in pulmonary inflammation. An update on TRP heteromers and their role in lung inflammation will be provided with this review. Keywords: heteromeric TRP assemblies; pulmonary inflammation; endothelial permeability; TRPC3/6; TRPV1/4; TRPC1/4 Citation: Zergane, M.; Kuebler, W.M.; Michalick, L. Heteromeric TRP Channels in Lung Inflammation. Cells 1. Introduction 2021, 10, 1654. https://doi.org Pulmonary microvascular endothelial cells are a key constituent of the blood air bar- /10.3390/cells10071654 rier that has to be extremely thin (<1 µm) to allow for rapid and efficient alveolo-capillary gas exchange.